Severity, not a blended score
Every finding lands in Must fix, Needs review, or Informational, so triage takes minutes instead of a meeting.
Patent pending phonetic and orthographic screeningAI Powered Regulatory
AI Powered Regulatory
Naming
LexiAI screens candidate brand names against FDA and EMA approved drug data, flags drug class stem clashes, and generates new candidates that pass the same checks.
Run a free name check Built on openFDA and EMA published data
The problem
A single similarity score hides the finding that sinks a name
Name screening usually means checking candidates by hand against several databases, then collapsing everything into one composite number. A stem clash and a weak phonetic match end up looking the same.
LexiAI separates findings by severity, so your team sees what must change, what needs a closer look, and what is only context.
What you get
Screening your naming team can act on
Real regulator data
Candidates are checked against approved names from FDA and EMA records. UK MHRA coverage is next.
Stem clashes caught early
Drug class stems derived from US government drug data are flagged before a candidate reaches formal review.
Generation that checks itself
New candidates are verified against stems, approved names, trademarks, and OPDP constraints before you ever see them.
How it works
From candidate list to a shortlist worth reviewing
- 01
Enter your candidates
Paste the names your team is considering and pick the markets that matter, FDA, EMA, or both.
- 02
Review tiered findings
See stem matches, orthographic and phonetic similarity, and exact matches, each sorted by severity.
- 03
Generate cleaner alternatives
Ask for new candidates. Each one is checked against the same rules before it reaches your shortlist.
Data and proof
Grounded in public regulatory records
US dataopenFDA
Approved drug names and product records from FDA.
EU dataEMA
Authorised medicine names published by the European Medicines Agency.
MethodPatent pending
Phonetic and orthographic conflict screening is covered by a filed US provisional application.
FAQ
Questions naming teams ask
Which markets does LexiAI cover?
FDA and EMA today. UK MHRA is the next market we are adding. Other markets stay hidden until real regulator data is available for them.
Does LexiAI replace a full naming review?
No. Screening results and generated names are suggestions. Every name still needs to go through your complete regulatory, trademark, and legal review.
What does Must fix mean?
A finding that would very likely stop the name, such as a drug class stem match. Needs review covers similarity that a person should judge. Informational is context only.
Where does the data come from?
Approved names come from openFDA and EMA published records. Drug class stems come from a list LexiAI builds from US government drug data.
How are new names generated?
LexiAI generates candidates, then verifies each one against stems, approved names, trademarks, and OPDP constraints. Names that fail are dropped before you see them.
Is my candidate list kept confidential?
{{data handling and confidentiality policy}}
What does it cost?
The name check is free to run. {{paid plan details}}